Idogen: Q1 Report Comment

Redeye leaves a comment on Idogen following the report for the first quarter of 2021, which did not include any significant surprises. We reiterate our Base case of SEK 5 per share.

FE

Filip Einarsson

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.